Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.
作者信息
Gökbuget Nicola, Zugmaier Gerhard, Klinger Matthias, Kufer Peter, Stelljes Matthias, Viardot Andreas, Horst Heinz A, Neumann Svenja, Brüggemann Monika, Ottmann Oliver G, Burmeister Thomas, Wessiepe Dorothea, Topp Max S, Bargou Ralf
机构信息
Center of Internal Medicine, Goethe University, Frankfurt, Germany.
Amgen Research (Munich) GmbH, Germany
出版信息
Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12.
Abstract
摘要
相似文献
1
Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia.在一项关于博纳吐单抗治疗B系急性淋巴细胞白血病微小残留病患者的2期研究中的长期无复发生存率
Haematologica. 2017 Apr;102(4):e132-e135. doi: 10.3324/haematol.2016.153957. Epub 2017 Jan 12.
2
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.在一项blinatumomab 治疗 B 系 ALL 患者微小残留病的 2 期研究中，血液学无复发生存的长期随访结果。
Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.
3
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.异基因造血干细胞移植后微小残留病的清除及高危成人急性淋巴细胞白血病临床结局的预测
Haematologica. 2007 May;92(5):612-8. doi: 10.3324/haematol.10965.
4
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.博纳吐单抗治疗复发/难治性B前体急性淋巴细胞白血病老年患者：两项2期研究的结果
Cancer. 2016 Jul 15;122(14):2178-85. doi: 10.1002/cncr.30031. Epub 2016 May 3.
5
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.儿童移植后复发/难治性B前体急性淋巴细胞白血病通过使用T细胞接合双特异性抗体博纳吐单抗治疗显示出持久缓解。
Haematologica. 2014 Jul;99(7):1212-9. doi: 10.3324/haematol.2013.100073. Epub 2014 Apr 11.
6
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.在接受博纳吐单抗治疗后达到微小残留病（MRD）缓解的复发/难治性急性淋巴细胞白血病（ALL）患者中的长期生存和T细胞动力学
Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19.
7
Durable remissions in positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation.使用博纳吐单抗和干细胞移植治疗阳性急性淋巴细胞白血病的持久缓解。
Haematologica. 2019 Jun;104(6):e244-e247. doi: 10.3324/haematol.2018.210104. Epub 2019 Feb 14.
8
Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant.同时使用博纳吐单抗和供体淋巴细胞输注治疗异基因造血细胞移植后复发的前B细胞急性淋巴细胞白血病。
Bone Marrow Transplant. 2016 Sep;51(9):1253-5. doi: 10.1038/bmt.2016.104. Epub 2016 Apr 18.
9
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Blinatumomab 治疗成人复发/难治性 B 前体急性淋巴细胞白血病患者的安全性和疗效：一项多中心、单臂、2 期研究。
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
10
Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.成人急性淋巴细胞白血病的表达谱分析确定了一个以高无反应率和复发率为特征的BCR-ABL1样亚组。
Haematologica. 2015 Jul;100(7):e261-4. doi: 10.3324/haematol.2014.117424. Epub 2015 Mar 13.
引用本文的文献
1
Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia.成人B细胞急性淋巴细胞白血病中基于抗体的及其他新型药物
Cancers (Basel). 2025 Feb 25;17(5):779. doi: 10.3390/cancers17050779.
2
GNA15 induces drug resistance in B cell acute lymphoblastic leukemia by promoting fatty acid oxidation via activation of the AMPK pathway.GNA15通过激活AMPK途径促进脂肪酸氧化，从而诱导B细胞急性淋巴细胞白血病产生耐药性。
Mol Cell Biochem. 2025 Jun;480(6):3719-3733. doi: 10.1007/s11010-024-05198-4. Epub 2025 Jan 15.
3
Short-Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A Retrospective Single-Center Study.短疗程博纳吐单抗治疗作为复发/难治性B细胞急性淋巴细胞白血病进一步挽救治疗的桥梁：一项回顾性单中心研究
Cancer Med. 2024 Dec;13(24):e70515. doi: 10.1002/cam4.70515.
4
Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia.双特异性 T 细胞衔接器在儿童 B 急性淋巴细胞白血病中的应用。
Haematologica. 2024 Jun 1;109(6):1668-1676. doi: 10.3324/haematol.2023.283818.
5
All about blinatumomab: the bispecific T cell engager immunotherapy for B cell acute lymphoblastic leukemia.关于博纳吐单抗：用于B细胞急性淋巴细胞白血病的双特异性T细胞衔接器免疫疗法。
Hematol Transfus Cell Ther. 2024 Apr-Jun;46(2):192-200. doi: 10.1016/j.htct.2023.06.006. Epub 2023 Jul 31.
6
Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia.急性淋巴细胞白血病异基因造血细胞移植后预防和克服复发的新策略。
Front Immunol. 2023 Jun 8;14:1191912. doi: 10.3389/fimmu.2023.1191912. eCollection 2023.
7
PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia.PAX5 通过表观遗传调控 CD58 的转录，调节急性淋巴细胞白血病中blinatumomab 的反应。
Sci Adv. 2022 Dec 14;8(50):eadd6403. doi: 10.1126/sciadv.add6403.
8
Immunotherapy and Allogeneic Bone Marrow Transplantation in B Acute Lymphoblastic Leukemia: How to Sequence?B 急性淋巴细胞白血病的免疫疗法和异基因骨髓移植：如何安排顺序？
Clin Hematol Int. 2022 May 11;4(1-2):11-20. doi: 10.1007/s44228-022-00006-6. eCollection 2022 Jun.
9
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.复发/难治性弥漫性大B细胞淋巴瘤患者治疗的当前选择与未来展望
Ther Adv Hematol. 2022 Jun 28;13:20406207221103321. doi: 10.1177/20406207221103321. eCollection 2022.
10
Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies.双特异性抗体在血液系统恶性肿瘤中的临床开发与治疗应用
Cancer Treat Res. 2022;183:287-315. doi: 10.1007/978-3-030-96376-7_11.
本文引用的文献
1
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.在接受博纳吐单抗治疗后达到微小残留病（MRD）缓解的复发/难治性急性淋巴细胞白血病（ALL）患者中的长期生存和T细胞动力学
Blood. 2015 Dec 10;126(24):2578-84. doi: 10.1182/blood-2015-06-649111. Epub 2015 Oct 19.
2
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.Blinatumomab 治疗成人复发/难治性 B 前体急性淋巴细胞白血病患者的安全性和疗效：一项多中心、单臂、2 期研究。
Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16.
3
Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.抗 CD19 双特异性 T 细胞衔接蛋白blinatumomab 的 II 期临床试验显示，复发或难治性 B 前体急性淋巴细胞白血病患者有血液学和分子缓解。
J Clin Oncol. 2014 Dec 20;32(36):4134-40. doi: 10.1200/JCO.2014.56.3247. Epub 2014 Nov 10.
4
Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia.在接受blinatumomab治疗的微小残留病阳性B前体急性淋巴细胞白血病患者中血清免疫球蛋白水平的长期随访
Blood Cancer J. 2014 Sep 5;4(9):244. doi: 10.1038/bcj.2014.64.
5
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL.在一项blinatumomab 治疗 B 系 ALL 患者微小残留病的 2 期研究中，血液学无复发生存的长期随访结果。
Blood. 2012 Dec 20;120(26):5185-7. doi: 10.1182/blood-2012-07-441030. Epub 2012 Sep 28.
6
Blinatumomab: a historical perspective.Blinatumomab：历史视角。
Pharmacol Ther. 2012 Dec;136(3):334-42. doi: 10.1016/j.pharmthera.2012.07.013. Epub 2012 Aug 24.
7
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.B 系急性淋巴细胞白血病患者对 T 细胞结合 CD19/CD3 双特异性 BiTE 抗体blinatumomab 持续输注的免疫药理学反应。
Blood. 2012 Jun 28;119(26):6226-33. doi: 10.1182/blood-2012-01-400515. Epub 2012 May 16.
8
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.急性淋巴细胞白血病伴分子学复发的成年患者预后不良，是干细胞移植和靶向治疗的候选人群。
Blood. 2012 Aug 30;120(9):1868-76. doi: 10.1182/blood-2011-09-377713. Epub 2012 Mar 22.
9
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.针对化疗耐药的 B 系急性淋巴细胞白血病患者微小残留病灶的 T 细胞结合抗体blinatumomab 的靶向治疗可带来高缓解率和延长无白血病生存。
J Clin Oncol. 2011 Jun 20;29(18):2493-8. doi: 10.1200/JCO.2010.32.7270. Epub 2011 May 16.
Zotero 插件